8-K: MoonLake Immunotherapeutics Receives Positive Regulatory Feedback for Phase 3 Psoriatic Arthritis Program

MoonLake Immunotherapeutics has secured positive feedback from both the FDA and EMA for its Phase 3 program of sonelokimab in psoriatic arthritis, paving the way for trial initiation.

Summary

• MoonLake Immunotherapeutics has received positive feedback from both the FDA and EMA regarding its Phase 3 program for sonelokimab in psoriatic arthritis (PsA).
• The Phase 3 program, named IZAR, will consist of two trials: IZAR-1 focusing on biologic-naive patients and radiographic progression, and IZAR-2 focusing on TNF-IR patients with a risankizumab reference arm.
• The trials will test 60mg and 120mg doses of sonelokimab, with a total Phase 3 population of approximately 1,500 patients.
• The primary endpoint readout for the IZAR program is expected by the end of 2026.
• The company also has ongoing Phase 3 trials for sonelokimab in hidradenitis suppurativa (HS) following positive regulatory feedback earlier in the year.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful regulatory feedback and the advancement of the Phase 3 program. The company is making good progress in its clinical development.

Positives

• The positive feedback from both the FDA and EMA provides a clear regulatory path for the Phase 3 program in psoriatic arthritis.
• The IZAR program includes a risankizumab reference arm in the IZAR-2 trial, which is a first for a PsA trial.
• The company is advancing three Phase 3 programs by the end of 2024, addressing two inflammatory indications.
• The Phase 3 trial design is in line with the company's previous communications and guidance.
• The company has a strong focus on inflammatory diseases with unmet needs.

Risks

• The company's limited operating history and reliance on third parties for clinical trials pose risks.
• There are risks associated with enrolling patients in clinical trials.
• Healthcare reform measures could reduce demand for the company's product candidates.
• The company is subject to risks and uncertainties that could cause actual results to differ materially from forward-looking statements.

Future Outlook

The company anticipates initiating the Phase 3 program in PsA in Q4 2024 and expects the primary endpoint readout by the end of 2026. They also plan to initiate a Phase 2 trial for palmo-plantar pustulosis (PPP) and a Phase 3 trial in juvenile HS in 2024.

Management Comments

• Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, stated that the recent regulatory milestones for PsA mark the second significant achievement for MoonLake, building on the positive FDA and EMA feedback for HS earlier this year.
• He also mentioned that by the end of 2024, they will have independently commenced three Phase 3 programs addressing two inflammatory indications.

Industry Context

This announcement is significant as it demonstrates progress in the development of new treatments for inflammatory diseases, specifically psoriatic arthritis, which affects a substantial portion of the population. The inclusion of a risankizumab reference arm in the IZAR-2 trial is notable as it allows for direct comparison with an existing treatment.

Comparison to Industry Standards

• The inclusion of a risankizumab reference arm in the IZAR-2 trial is a notable comparison to other treatments in the market, such as Cosentyx (secukinumab) and Humira (adalimumab), which are commonly used for PsA.
• The company's focus on achieving ACR50 response at week 16 aligns with industry standards for measuring efficacy in PsA trials.
• The use of Nanobody technology is a novel approach compared to traditional antibody therapies, potentially offering advantages in terms of tissue penetration and manufacturing.

Stakeholder Impact

• Shareholders will likely view the positive regulatory feedback as a positive development.
• Patients with psoriatic arthritis and hidradenitis suppurativa may benefit from the development of new treatment options.
• Employees of MoonLake will be involved in the execution of the Phase 3 programs.

Next Steps

• The company plans to initiate the Phase 3 IZAR program in Q4 2024.
• They will continue patient enrollment in the VELA program for HS.
• A Phase 2 trial for palmo-plantar pustulosis (PPP) is expected to be initiated in 2024.
• A Phase 3 trial is expected to initiate in juvenile HS.
• Phase 2 trials in radiographic and non-radiographic axial spondyloarthritis (axSpA) and PsA are expected to start in 2024.

Key Dates

Keywords

sonelokimab, psoriatic arthritis, hidradenitis suppurativa, Phase 3, FDA, EMA, IZAR, clinical trials, Nanobody, inflammatory diseases